biotech news today obesity drugs glp-1 ADA '26: Lilly's dominance, Pfizer's 'foundational' drug and Roche's 'me-too' option Unpacking $100B+ Obesity Market Opportunity:
Description
Baxter, J
doi:10.1016/j.bbrc.2017.06.031 41
Ozempic and Mounjaro, on the other hand, work by imitating gut hormones that increase your bodys insulin production when youre eating, slow down how quickly food moves through the digestive tract, and increase satiety and fullness when youre eating, adds King
From there, they signal your pancreas to release insulin, suppress glucagon to prevent excess glucose from entering your bloodstream, slow stomach emptying so nutrients are absorbed more gradually, and send satiety signals to your brain
GLP-1 medicines might slightly increase the risk of gallbladder disease
PubMed Central PMCID: PMC12125019
